Skip to main content

Table 1 Relative serious infectious event risk associated with baseline age categories and medically treated comorbidities included in age-adjusted comorbidity index

From: Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

 

HR (95% CI)

Weight in the AACIa

Category

RCT CZP (n = 1224)

All CZP (n = 1506)

Age, years

<50

Reference

Reference

0

≥50 to < 60

1.29 (0.58–2.87)

1.39 (0.99–1.96)

1

≥60 to < 70

1.14 (0.44–2.94)

1.40 (0.92–2.12)

1

≥70

2.18 (0.70–6.84)

2.93 (1.69–5.09)

3

Diabetes mellitus

1.98 (0.59–6.58)

1.61 (0.90–2.89)

2

COPD/asthma

2.67 (0.77–9.27)

1.29 (0.56–2.97)

2

Cardiac disorder

N/C

1.33 (0.52–3.43)

0

Hypertension

1.34 (0.69–2.63)

0.96 (0.70–1.32)

0

Hyperlipidemia

2.39 (0.82–6.93)

1.47 (0.81–2.67)

2

Thyroid disorder

N/C

0.87 (0.42–1.78)

0

Osteoporosis

2.30 (0.98–5.39)

1.16 (0.73–1.86)

2

Depression

1.00 (0.22–4.51)

1.46 (0.75–2.83)

1

  1. Abbreviations: SIE Serious infectious event, AACI Age-adjusted comorbidity index, CZP Certolizumab pegol, COPD Chronic obstructive pulmonary disease, N/C Not calculable (no patients with the indicated comorbidity experienced an SIE during the randomized controlled trials), RCT CZP Patients randomized to CZP in the RAPID1/RAPID2 randomized controlled trials, All CZP All patients treated with CZP during the RAPID1/RAPID2 randomized controlled trials and/or open label extensions
  2. HRs were derived from a Cox proportional hazards model fitted with the indicated age categories and medically treated comorbidities; no other baseline covariates were included
  3. aWeight of each category in the AACI was based on the average HR between the RCT CZP and All CZP populations (HR ≥ 1.2 and < 1.5, weight = 1; HR ≥ 1.5 and < 2.5, weight = 2; HR ≥ 2.5 and < 3.5, weight = 3)